Medications

Atezolizumab prolongs survival in NSCLC with PD-L1 expression

(HealthDay)—For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in longer overall survival than chemotherapy, according to a study ...

Oncology & Cancer

Immunotherapy improves survival in advanced bladder cancer patients

An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University ...

page 1 from 3